Ge Li

Ge Li

Auto-generated profile, based on publicly available information

Ge Li

University of Washington School of Medicine, Seattle, WA USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WWWei Wang
Wei Wang
JWJianping Wu
Jianping Wu
KBKaren Bernard
Karen Bernard
GLGe Li
Ge Li
GWGuangyu Wang
Guangyu Wang
KKKevin L. Kirk
Kevin L. Kirk
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) channel, an ATP binding cassette (ABC) transporter. CFTR gating is linked to ATP binding and dimerization of its two nucleotide binding domains (NBDs). Channel activation also requires phosphorylation of the R domain by poorly understood mechanisms. Unlike conventional ligand-gated channels, CFTR is an ATPase for which ligand (ATP) release typically involves nucleotide hydrolysis. The extent to which CFTR gating conforms to classic allosteric schemes of ligand activation is unclear. Here, we describe point mutations in the CFTR cytosolic loops that markedly increase ATP-independent (constitutive) channel activity. This finding is consistent with an allosteric gating mechanism in which ligand shifts the equilibrium between inactive and active states but is not essential for channel opening. Constitutive mutations mapped to the putative symmetry axis of CFTR based on the crystal structures of related ABC transporters, a common theme for activating mutations in ligand-gated channels. Furthermore, the ATP sensitivity of channel activation was strongly enhanced by these constitutive mutations, as predicted for an allosteric mechanism (reciprocity between protein activation and ligand occupancy). Introducing constitutive mutations into CFTR channels that cannot open in response to ATP (i.e., the G551D CF mutant and an NBD2-deletion mutant) substantially rescued their activities. Importantly, constitutive mutants that opened without ATP or NBD2 still required R domain phosphorylation for optimal activity. Our results confirm that ( i ) CFTR gating exhibits features of protein allostery that are shared with conventional ligand-gated channels and ( ii ) the R domain modulates CFTR activity independent of ATP-induced NBD dimerization.

21 November 2014 in Respiratory Medicine
Verified
Journal Article
Open access
PDF file
SBSeth A. Brodie
Seth A. Brodie
GLGe Li
Ge Li
JBJohann C. Brandes
Johann C. Brandes
Reduced expression or epigenetic silencing of the mitotic checkpoint gene “checkpoint with fork-head and ringfinger domains” (CHFR) has recently been identified as powerful predictor for taxane sensitivity in gastric-, colon and lung cancer [ 1 x [1] Brandes, J.C., van Engeland, M., Wouters, K.A., Weijenberg, M.P., and Herman, J.G. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis. 2005; 26: 1152–1156 Crossref | PubMed | Scopus (69) | Google Scholar See all References , 2 x [2] Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruine AP, Herman JG, van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. Google Scholar See all References , 3 x [3] Pillai, R.N., Brodie, S.A., Sica, G.L., Shaojin, Y., Li, G., Nickleach, D.C., Yuan, L., Varma, V.A., Bonta, D., Herman, J.G., Brock, M.V., Ribeiro, M.J., Ramalingam, S.S., Owonikoko, T.K., Khuri, F.R., and Brandes, J.C. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res – Off J Am Assoc Cancer Res. 2013; 19: 1603–1611 Crossref | PubMed | Scopus (15) | Google Scholar See all References ]. Reduced CHFR expression in patients with non-small lung cancer (NSCLC) who received first-line chemotherapy with carboplatin and paclitaxel predicts clinical benefit (81% vs. 48%, p = 0.03) and overall survival (HR = 0.24; 95% CI, 0.1–0.58%; P = 0.002) [ 3 x [3] Pillai, R.N., Brodie, S.A., Sica, G.L., Shaojin, Y., Li, G., Nickleach, D.C., Yuan, L., Varma, V.A., Bonta, D., Herman, J.G., Brock, M.V., Ribeiro, M.J., Ramalingam, S.S., Owonikoko, T.K., Khuri, F.R., and Brandes, J.C. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res – Off J Am Assoc Cancer Res. 2013; 19: 1603–1611 Crossref | PubMed | Scopus (15) | Google Scholar See all References ] [3] . These are important observations since it allows physicians to select patients for microtubular-targeted therapy based on their CHFR expression status, and furthermore, to target CHFR pharmacologically to overcome taxane resistance in patients whose tumors display high CHFR expression. NSCLC can be molecularly characterized by the presence of mutations in oncogenes and tumor suppressor genes, which frequently determine the therapeutic approach to these tumors. Targeted therapies for tumors with EGFR mutations [ 4 x [4] Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–2139 Crossref | PubMed | Scopus (8594) | Google Scholar See all References , 5 x [5] Sordella, R., Bell, D.W., Haber, D.A., and Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 1163–1167 Crossref | PubMed | Scopus (1313) | Google Scholar See all References , 6 x [6] Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497–1500 Crossref | PubMed | Scopus (7295) | Google Scholar See all References ] and Alk-translocations [ 7 x [7] Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Janne, P.A., Costa, D.B., Varella-Garcia, M., Kim, W.H., Lynch, T.J., Fidias, P., Stubbs, H., Engelman, J.A., Sequist, L.V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G.C., Shreeve, S.M., Ratain, M.J., Settleman, J., Christensen, J.G., Haber, D.A., Wilner, K., Salgia, R., Shapiro, G.I., Clark, J.W., and Iafrate, A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693–1703 Crossref | PubMed | Scopus (3136) | Google Scholar See all References ] [7] are available and new targets such as RET and ROS1 fusions, BRAF, and ERBB2, are rapidly emerging. Nonetheless, a large percentage of lung cancers are not driven by single oncogene mutations and improvements in better selection of standard chemotherapy drugs or the development of novel targeted approaches to overcome chemo-resistance are essential for patients with these tumors. To find the most appropriate place for CHFR testing in the ever more complex algorithms for biomarker analysis in NSCLC, it is important to determine if reduced expression of CHFR is tied exclusively to certain molecularly defined subtypes of NSCLC or, conversely, if CHFR expression is independent from the presence of lung cancer specific mutations. We therefore analyzed CHFR expression and frequent relevant mutations in NSCLC reported in The Cancer Genome Atlas (TCGA) for both adenocarcinoma (EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA) and squamous cell carcinoma (FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR).

16 July 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
GLGe Li
Ge Li
HYHaifan Yang
Haifan Yang
YCYong Cheng
Yong Cheng
XZXin Zhao
Xin Zhao
XLXu Li
Xu Li
RJRui Jiang
Rui Jiang
Background: Papillary renal cell carcinoma (pRCC) accounting for near 20% of renal cell carcinoma is the second most common histological subtype. MiRNAs have been demonstrated to played significant roles on predicting prognosis of patients with tumors. An appropriate and comprehensive miRNAs analysis based on a great deal of pRCC samples from The Cancer Genome Atlas (TCGA) will provide perspective in this field. Methods: We integrated the expression of mRNAs, miRNAs and the relevant clinical data of 321 pRCC patients recorded in the TCGA database. The survival-related differential expressed miRNAs (sDEmiRs) were estimated by COX regression analysis. The high-risk group and the low-risk group were separated by the median risk score of the risk score model (RSM) based on three screened sDEmiRs. The target genes, underlying molecular mechanisms of these sDEmiRs were explored by computational biology. The expression levels of the three sDEmiRs and their correlations with clinicopathological parameters were further validated by qPCR. Results: Based on univariate COX analysis (P < 0.001), eighteen differential expressed miRNAs (DEmiRs) were remarkably related with the overall survival (OS) of pRCC patients. Three sDEmiRs with the most significant prognostic values (miR-34a-5p, miR-410-3p and miR-6720-3p) were employed to establish the RSM which was certified as an independent prognosis factor and closely correlated with OS. In the verification of clinical samples, the overexpression of miR-410-3p and miR-6720-3p were detected to be associated with the advanced T-stages, while miR-34a-5p showed the reversed results. Conclusion: The study developed a RSM based on the identified sDEmiRs with significant prognosis prediction values for pRCC patients. The results pave the avenue for establishing and optimizing a reliable and referable risk assessing model and provide novel insight into the researches of biomarkers and clinical treatment strategies.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
TPTaylor J Pedersen
Taylor J Pedersen
JFJaqueline A Flores
Jaqueline A Flores
TSTejaswi D Sudhakar
Tejaswi D Sudhakar
CACole E Anderson
Cole E Anderson
EPElaine R Peskind
Elaine R Peskind
AIAlzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative
Background: The Hachinski ischemic score (HIS) scale is used to exclude as much as possible, individuals with dominant cerebrovascular pathology from those with dominant AD pathology. White matter hyperintensities (WMH) are the gold‐standard for evaluating cerebrovascular pathology and linked to worsening cognitive impairment. HIS ≤ 4 are used to minimize non‐AD pathology in ADNI participants. Here we sought to understand whether HIS scores for hypertension (HMHYPERT) in ADNI3 were associated with greater WMH burden (and hence cerebrovascular pathology) even within individuals with HIS ≤ 4.Method: We compared HMHYPERT scores between individuals with normal cognition (CN) and with mild cognitive impairment (MCI), and participants and correlated with percent WMH burden. A total of 263 subjects screened for ADNI3 (92 MCI [38 F], age = 73 ± 6; 146 CN [94 F], age = 74 ± 7) who had HIS scores and FLAIR MRI acquisitions within a year of each other. 25 All AD participants were excluded. WMH burden was calculated by segmenting them using the Lesion Segmentation Toolbox and normalizing their volume by total intracranial volume. We used the HMHYPERT as a vascular risk factor, excluding those with any focal neurological symptoms. For analysis, we dichotomized participants into those with HMHYPERT = 0 and HMHYPERT>0. To examine whether a non‐zero HMHYPERT score corresponds to greater WMH burden, we examined the prevalence of WMH in between these 2 groups and within the MCI and CN groups.Result: Although not significant, HMHYPERT scores were higher in MCI. (Fig. 1A, MCI = 0.48±0.50, CN = 0.39±0.49). We found a greater proportion of MCI subjects had HMHYPERT>0 than CN subjects (Fig. 1B, HMHYPERT = 0: CN = 61.0% and MCI = 52.2%; HMHYPERT > 0: CN = 40.0% and MCI = 48.1%). WMH burden was greater in MCI (0.33±0.53) than CN (0.20±0.32) (Fig. 2A). MCI participants with HMHYPERT>0 had the highest WMH burden followed by MCI participants with HMHYPERT = 0, CN with HMHYPERT >0, and CN with HMHYPERT = 0 had the lowest WMH burden. (Fig. 2B).Conclusion: Cerebrovascular pathology increases significantly with diagnosis, but its severity increases further with findings of hypertension even when total HIS ≤ 4.